You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
本港新增4宗新冠確診輸入個案及1宗Omicron個案
阿思達克 12-10 17:09
衛生署衛生防護中心公布,截至今日(10日)零時零分,中心正調查4宗新增新冠肺炎確診輸入個案,當中3宗涉及變異病毒株的感染,其餘1宗的變異病毒株檢測結果待定。個案涉及兩男兩女,年齡介乎15至57歲。1人由A組指明地區(高風險)抵港,3人由B組指明地區(中風險)抵港。3人於抵港時在香港國際機場臨時樣本採集中心「檢測待行」的檢測結果呈陽性,其餘1人於指定檢疫酒店檢疫期間確診。 上述個案中,個案編號12486涉及一名57歲男病人,居於薄扶林域多利道550號碧瑤灣16座。他於11月18日離港經新加坡前往越南,其後從越南經航班CX764於12月8日抵港,抵港時在臨時樣本採集中心抽取樣本進行的新冠病毒檢測結果呈陽性。病人沒有病徵,Ct值少於30,並確認帶有L452R變異病毒株(N501Y和E484K則呈陰性)。他於3月22日及4月12日於香港接種兩劑復必泰疫苗。個案的流行病學調查和個案追蹤仍然進行中。為審慎起見,他於潛伏期在港曾居住的地點會納入強制檢測公告。任何於指定期間曾身處相關指明地方內的人士,須在指定日子接受強制檢測。 至今本港個案累計12,483宗(包括12,482宗確診個案和一宗疑似個案)。於11月26日至12月9日的過去14天累計報告61宗個案,全屬輸入個案。 同時,中心匯報昨日(9日)公布確診輸入個案12478的調查進展,該名37歲男病人於12月7日從美國經航班CX881抵港,於抵港時在香港國際機場臨時樣本採集中心「檢測待行」的檢測結果呈陽性。病人6月2日及6月25日在香港接種兩劑復必泰疫苗,他沒有病徵,入院後於12月7日進行的檢測對抗體呈陽性反應,入院後進行的檢測Ct值少於20。根據衛生署公共衛生化驗服務處進行的全基因組測序分析結果,確認個案帶有需要關注的變異病毒株Omicron。 另外,由於國泰航空(00293.HK)營運於12月8日由越南胡志明市飛抵香港的航班(CX764)有3名乘客經抵港檢測而確診新冠病毒,衛生署遂引用《預防及控制疾病(規管跨境交通工具及到港者)規例》(第599H章),禁止國泰航空營運的客機在12月10至23日期間從胡志明市著陸香港。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account